Basic drug introduction and applicable population description of Erdafitinib

Erdafitinib is an oral small molecule tyrosine kinase inhibitor specifically designed to target mutations and fusion abnormalities in the fibroblast growth factor receptor (FGFR) family. The drug shows good anti-tumor activity by inhibiting the abnormal activation of the FGFR signaling pathway and blocking the growth and spread of tumor cells. Erdafitinib is one of the few clinically approved targeted drugs for the treatment of solid tumors associated with FGFR gene alterations, and represents the development direction of precision medicine.

Erdafitinib is mainly suitable for patients with locally advanced or metastatic urothelial carcinoma who carry FGFR3 or FGFR2 gene mutations or fusions. These patients usually have received at least one front-line chemotherapy with limited response or are unable to tolerate standard chemotherapy. After genetic testing confirms FGFR abnormalities, doctors can choose erdafitinib as a follow-up treatment plan for patients to help delay disease progression and improve quality of life.

In addition, the application of erdafitinib continues to expand, and relevant clinical trials are also evaluating its efficacy in other FGFR related tumors, such as cholangiocarcinoma, lung cancer, etc. Although the current main approved indication is urothelial cancer, with the deepening of research, it may cover more tumor types in the future and become an important treatment option for patients with various solid tumors.

When using erdafitinib, patients should take it orally as directed by their doctor and closely monitor serum phosphorus levels and eye health, as the drug may cause hyperphosphatemia and vision-related side effects. Detailed genetic testing should be performed to confirm FGFR status before treatment, and regular follow-up is required during treatment to evaluate efficacy and safety. Overall, erdafitinib provides a new precision treatment option for tumor patients with FGFR gene abnormalities, filling the treatment gap for some patients.

Reference link:https://www.balversa.com/